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Up to 86% of uterine leiomyomas harbour somatic mutations in mediator complex subunit 12 (MED12). 
These mutations have been associated with conventional histology, smaller tumour size, and larger 
number of tumours within the uterus. Prior studies, with limited sample sizes, have failed to detect 
associations between other clinical features and MED12 mutations. Here, we prospectively collected 
763 uterine leiomyomas and the corresponding normal myometrial tissue from 244 hysterectomy 
patients, recorded tumour characteristics, collected clinical data from medical records, and screened 
the tissue samples for MED12 mutations to assess potential associations between clinical variables 
and mutation status. Out of 763 leiomyomas, 599 (79%) harboured a MED12 mutation. In the analysis 
of tumour characteristics, positive MED12-mutation status was significantly associated with smaller 
tumour size, conventional histology, and subserous location, relative to intramural. In the analysis of 
clinical variables, the number of MED12-mutation-positive tumours showed an inverse association with 
parity, and the number of mutation-negative tumours showed a positive association with a history of 
pelvic inflammatory disease. This study confirmed the previously reported differences and discovered 
novel differentiating features for MED12-mutation-positive and -negative leiomyomas. These findings 
emphasise the relevance of specific driver mutations in genesis and presentation of uterine leiomyomas.
Uterine leiomyomas are steroid-hormone-dependent benign smooth muscle tumours with an overall 70 to 80% 
incidence by 50 years of age1. They cause significant morbidity and substantial cost2. Typically, an affected uterus 
contains multiple leiomyomas ranging from a few millimetres up to 30 centimetres in size3. These lesions are 
histologically benign, but some display malignant features; these represent rare histopathological variants, such 
as cellular or mitotically active leiomyomas4. Approximately 25% of women with leiomyomas display symptoms, 
which depend on the number, location, and size of the tumours5. Even small submucous leiomyomas can cause 
heavy and irregular menstrual bleeding, whereas large intramural or subserous lesions can lead to pelvic pain, 
pressure, and urinary distress. Medication such as tranexamic acid and hormone therapy (HT) may relieve the 
symptoms, however, with a limited effect. Many patients therefore undergo surgical treatment; leiomyomas are 
the primary indication for hysterectomy.
Well-established risk factors for uterine leiomyomas include African origin, increasing age up to menopause, 
early menarche, nulliparity, infertility, family history of leiomyomas, and rare tumour susceptibility syndromes, 
particularly hereditary leiomyomatosis and renal cell cancer (HLRCC)1, 6–12. Obesity, alcohol intake, HT, repro-
ductive tract infections, hypertension, and hypothyroidism also seem to cause increased risk for leiomyomas, 
whereas smoking and diabetes reduce their incidence6, 8, 10, 11, 13–15. Oral contraceptive users may be at reduced 
risk6, 10, although contradicting results exist9.
Up to 86% of uterine leiomyomas harbour site-specific mutations in mediator complex subunit 12 (MED12)16–27. 
Based on gene expression profiling, leiomyomas carrying these mutations represent a molecularly distinct sub-
type28. Furthermore, MED12 mutations are associated with smaller tumour size and larger number of tumours 
within the uterus, and they are less frequent in histopathological leiomyoma variants16, 17, 20–23, 25, 27. Earlier 
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studies, with limited sample sizes, have failed to detect underlying associations between other clinical factors 
and MED12-mutation status, however17, 18, 20, 22, 24. To scrutinise these associations further, we have prospectively 
collected a series of 763 leiomyomas from 244 hysterectomy patients with comprehensive clinical data. These 
samples underwent screening for MED12-hotspot mutations, after which we tested the association of the muta-
tion status with tumour characteristics and clinical factors.
Results
Out of 244 patients, 177 (73%) had at least one MED12-mutation-positive leiomyoma, and out of 763 uterine 
leiomyomas, 6 (1%) harboured a mutation in exon 1 and 593 (78%) in exon 2 (see Supplementary Table S1 for 
more detailed information). Table 1 presents the frequencies of MED12 mutations for different leiomyoma sub-
groups. The majority of mutations, observed in 415 (54%) leiomyomas, were missense mutations affecting codon 
44 (Fig. 1). All the mutations were heterozygous and somatic.
The median number of leiomyomas was 2 (range 1–16), the median number of MED12-mutation-positive 
tumours was 2 (range 0–16), and the median number of mutation-negative tumours was 1 (range 0–5) per patient. 
The number of MED12-mutation-positive and -negative leiomyomas were negatively correlated [Spearman’s 
correlation coefficient −0.52, P value (P)  = 1.6 × 10−18]. In addition, the number of MED12-mutation-positive 
tumours and the total number of leiomyomas were strongly correlated (Spearman’s correlation coefficient 0.87, 
P = 1.3 × 10−77), whereas the number of mutation-negative tumours and total number of leiomyomas showed no 
correlation.
First, to test whether tumour size, location and histotype are associated with the MED12-mutation status of 
the leiomyomas, we fit a generalised estimating equations (GEE) model. Positive mutation status was significantly 
associated with smaller tumour size (P = 4.2 × 10−9), conventional histology (P = 0.0013), and subserous relative 
to intramural location (P = 0.00082, Table 2).
Subgroup
MED12-mutation 
positive n (%) N
All leiomyomas 599 (78.5) 763
Leiomyomas from
 Finns 535 (78.8) 679
 non-Finns 64 (76.2) 84
Histotype
 conventional leiomyoma 589 (79.7) 739
 cellular leiomyoma 4 (40.0) 10
 highly cellular leiomyoma 1 (25.0) 4
 mitotically active leiomyoma 1 (50.0) 2
 cellular and mitotically active leiomyoma 2 (100.0) 2
 leiomyoma with bizarre nuclei 1 (50.0) 2
 epithelioid leiomyoma 1 (100) 1
 lipoleiomyoma 0 (0) 3
Table 1. MED12 mutations in leiomyoma subgroups.
Figure 1. MED12-mutation spectrum in 763 uterine leiomyomas. In addition to negative mutation status 
(wild-type), missense mutations affecting different codons, and in-frame insertion and/or deletions (indel) in 
exon 2 or in intron 1- exon 2 junction and in exon 1 or exon 1 - intron 1 junction are shown separately. Codon 
44 mutations are represented in more detail.
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Second, we examined the associations between clinical factors and the number of MED12-mutation-positive 
leiomyomas. Here, we used negative binomial regression to account for overdispersion in the corresponding 
Poisson model (overdispersion test P = 7.1 × 10−6). The number of mutation-positive tumours was inversely 
associated with parity (P = 0.00017, Table 3). In addition, postmenopausal women without HT had fewer 
mutation-positive tumours, in comparison to premenopausal women; however, after adjusting for multiple test-
ing, the outcome was not statistically significant (P = 0.0080). No associations were observed between the number 
of mutation-positive leiomyomas and age at hysterectomy, infertility, smoking status, body mass index (BMI), 
family history of leiomyomas, oral contraceptive use, history of pelvic inflammatory disease (PID) and chlamydia, 
hypertension, thyroid disorder, diabetes, or prior leiomyoma surgery.
Finally, we assessed the associations between the clinical factors and the number of MED12-mutation-negative 
leiomyomas with Poisson regression. The number of mutation-negative tumours showed a statistically significant 
association with a history of PID (P = 0.00024, Table 3). No associations were observed between the number of 
mutation-negative leiomyomas and any of the other above-mentioned clinical factors.
Discussion
This study examined the associations between MED12-mutation status, tumour characteristics, and various clin-
ical factors in a large sample set of leiomyomas. As novel findings, the MED12-mutation-positive tumours were 
associated with subserous type and their number was inversely associated with parity, whereas the number of 
mutation-negative tumours was associated with a history of PID. In addition, our data confirmed the previous 
findings that MED12-mutation-positive leiomyomas are smaller in size and more often histopathologically con-
ventional than mutation-negative lesions17, 20–23, 25, 27.
In this prospectively collected leiomyoma series, the frequency of MED12 mutations reached 79%, being 
among the highest ones reported. Both Finns and patients of non-Finnish origin harboured mutations with sim-
ilar frequencies. In prior studies with varying sample sizes and patient ethnicities, the mutation frequency in 
conventional leiomyomas has ranged from 31 to 86%, and in Finns, from 70 to 86%16–18, 20–27. The majority of the 
prior studies have only screened for exon 2 mutations, however. Here, 1% of leiomyomas harboured a mutation 
in exon 1, which is in line with the literature where the prevalence has ranged from 1 to 2%17, 19. Thus, exclusion 
of exon 1 mutations explains only a minor proportion of the variation seen in the reported mutation frequencies. 
One likely contributing factor explaining the different results is size bias: in some sample sets large lesions may 
have been preferred; this selects against MED12-mutation-positive tumours, ones usually smaller in size.
As expected, histopathological leiomyoma variants tended to be MED12-mutation negative. Nevertheless, 
42% of the variants harboured a MED12 mutation: a higher frequency than in previous works with mutation 
frequencies ranging from 0 to 21%21, 23, 25, 27. Due to the small number of leiomyoma variants in this study, how-
ever, it is difficult to draw definitive conclusions on their exact mutation frequencies. All three of the lipoleio-
myomas were mutation negative. Only one prior study has screened MED12 mutations from lipoleiomyomas, 
and similarly all four of the studied lesions were mutation negative21. Overall, our results are compatible with the 
previous notion that mechanisms other than MED12 mutations, such as high mobility group AT-hook 2 (HMGA2) 
aberrations, drive the majority of histopathological variants while the great majority of common leiomyomas are 
MED12-mutation positive23, 29–32.
This is, to our knowledge, the first study to show that positive MED12-mutation status is associated with sub-
serosal location of leiomyomas. Two prior studies have explored the association between MED12-mutation status 
and tumour location with negative results, possibly due to different study settings and smaller sample sizes18, 24. 
Brosens et al. have concluded that submucosal leiomyomas display significantly fewer clonal cytogenetic changes 
compared to the other types33. Myometrium consists of functionally and structurally distinct layers: the subendo-
metrial myometrium exhibits a cyclic pattern of steroid hormone receptor expression, whereas the outer layers of 
the uterine wall express these receptors continually34. Taken together, these data suggest that the differences in the 
myometrial layers influence the molecular mechanisms underlying leiomyoma development.
Leiomyoma 
characteristics
All 
leiomyomas 
(N = 763)
MED12-
mutation-
positive 
(n = 599)
MED12-
mutation-
negative 
(n = 164)
Multivariable-
adjusted 
regression 
coefficient 
[95% CI] P
Size (cm)1 3.0 (2.0–5.0) 3.0 (1.7–4.0) 4.0 (2.2–7.0) −0.18 [−0.24, −0.12] 4.2 × 10
−9
Histopathological variant 24 (3.3) 10 (1.7) 14 (8.5) −1.60 [−2.58, −0.63] 0.0013
Location2
 intramural 559 (73.2) 419 (69.9) 140 (85.4) reference 1
 subserous 88 (11.6) 80 (13.4) 8 (4.9) 0.82 [0.34, 1.30] 0.00082
 submucous 44 (5.8) 38 (6.3) 6 (3.7) 0.52 [−0.12, 1.16] 0.11
Table 2. Leiomyoma characteristics and results of the generalised estimating equations model including 
leiomyoma size, location and histotype (n = 683). Data are median (inter quartile range) or n (%) unless 
otherwise specified. To adjust for multiple comparisons, P < 0.00147 indicated statistical significance (the 
Bonferroni correction). CI = confidence interval. 115 missing values: 13 mutation-positive and 2 –negative. 272 
missing values: 62 mutation-positive and 10 –negative.
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In addition, our results confirmed the previous findings that smaller tumour size and larger number of 
tumours are associated with positive MED12-mutation status17, 20, 22, 24. The small size of mutation-positive 
lesions may result from the coexistence of multiple tumours, which jointly lead to clinical intervention sooner, 
whereas the solitary, typically intramural, mutation-negative tumours need to grow larger to manifest symptoms. 
Alternatively, the biological growth process may differ between these leiomyoma subtypes. The multiplicity of 
MED12-mutation-positive leiomyomas may derive from genetic predisposition and/or environmental factors 
rendering the myometrium susceptible to selection for MED12 mutations.
Intriguingly, a history of PID was associated with the number of MED12-mutation-negative tumours, whereas 
chlamydia infection, which can overlap with PID diagnosis, showed no association. A few epidemiological stud-
ies have observed an association between reproductive tract infections and increased risk for leiomyomas13, 14. 
Faerstein et al. observed increased odds for leiomyomas with a history of PID and chlamydia infection, as well 
as with past intrauterine device use when related to infectious complications, suggesting that inflammation 
may contribute to increased risk13. Furthermore, Moore et al. observed a negative association between chla-
mydia infection and multiple leiomyomas, and a similar trend for PID14, which is consistent with our result as 
mutation-negative leiomyomas are typically solitary. In the context of mutation-negative lesions, this finding is 
compatible with a proposed hypothesis that leiomyomas can occasionally develop via abnormal response to tis-
sue repair or inflammatory stimuli, leading to cell proliferation and fibrosis35. It is also possible that an infectious 
agent may have a direct tumourigenic effect, such as the Epstein-Barr virus, which is known to cause leiomyomas 
and leiomyosarcomas in immunosuppressed patients36.
Evidently, parity reduces the risk of leiomyomas, with risk declining as the number of births increases9, 10. 
According to one proposed mechanism, remodelling of the uterus after each pregnancy would induce lei-
omyoma regression; however, direct evidence is lacking37. The inverse association between the number of 
MED12-mutation-positive leiomyomas and parity suggests that births reduce the risk specifically for this lei-
omyoma subgroup. As Baird and Dunson reason, uterine involution may be more potent in eliminating small 
lesions, ones typically mutation-positive, whereas remnants of larger tumours would survive37. In addition, the 
mutation-positive and -negative tumours may respond differently to the changes in, for example, the hormonal 
environment during and after pregnancy. Furthermore, postmenopausal women without HT showed a trend 
towards fewer MED12-mutation-positive leiomyomas than premenopausal women; however, we observed a sim-
ilar, yet weaker, trend also with mutation-negative tumours, but due to the limited sample size no conclusions can 
be drawn. It is conceivable that MED12-mutation-positive and -negative leiomyomas may respond differently to 
hormone-level changes, as well as to treatments, such as selective progesterone receptor modulators.
The strength of this study is the large prospective sample set with comprehensive clinical data. On the other 
hand, the main shortcoming is the basic problem of any database survey; misclassification of variables is possible 
Patient characteristics
Median 
(IQR)/n 
(%) 
N = 244
NB model for number of 
MED12-mutation-positive 
leiomyomas (n = 241)
Poisson model for number of 
MED12-mutation-negative 
leiomyomas (n = 241)
Multivariable-
adjusted regression 
coefficient [95% CI] P
Multivariable-
adjusted regression 
coefficient [95% CI] P
Age at hysterectomy (y) 49 (45–54) 0.017 [−0.011, 0.046] 0.22 0.020 [−0.0099, 0.050] 0.19
Menopausal status
 premenopausal 178 (73.0) reference 1 reference 1
 current use of HT 33 (13.5) −0.16 [−0.67, 0.36] 0.54 −0.41 [−1.01, 0.15] 0.17
 postmenopausal, no HT 33 (13.5) −0.85 [−1.49, −0.22] 0.0080 −0.49 [−1.18, 0.16] 0.15
Parity 2 (0–2) −0.23 [−0.35, −0.10] 0.00017 0.069 [−0.054, 0.19] 0.26
Infertility 22 (9.0) 0.092 [−0.38, 0.59] 0.71 −0.18 [−0.83, 0.37] 0.54
Use of oral contraceptives 
(never/ever) 122 (50.0) −0.040 [−0.34, 0.26] 0.78 0.015 [−0.31, 0.34] 0.93
History of PID 11 (4.5) −0.17 [−0.87, 0.57] 0.63 1.05 [0.46, 1.59] 0.00024
History of chlamydia 10 (4.1) −0.75 [−1.58, 0.075] 0.076 −0.12 [−0.97, 0.58] 0.75
Prior myomectomy 24 (9.8) 0.41 [−0.045, 0.88] 0.075 −0.41 [−1.14, 0.20] 0.22
Family history of 
leiomyomas 38 (15.6) 0.32 [−0.051, 0.71] 0.091 0.061 [−0.39, 0.47] 0.78
Hypertension 59 (24.2) 0.024 [−0.35, 0.40] 0.90 0.20 [−0.19, 0.58] 0.31
Diabetes mellitus 16 (6.6) −0.13 [−0.75, 0.51] 0.69 0.29 [−0.36, 0.87] 0.35
Thyroid disease 24 (9.8) −0.21 [−0.70, 0.30] 0.40 −0.16 [−0.78, 0.39] 0.60
Body mass index (kg/m2)1 25.6 (23.1–29.8) 0.0052 [−0.027, 0.037] 0.74 0.0090 [−0.025, 0.043] 0.60
Smoker (never/ever)2 63 (26.1) 0.17 [−0.15, 0.49] 0.30 −0.016 [−0.38, 0.33] 0.93
Table 3. Characteristics of uterine leiomyoma patients and results from negative binomial and Poisson models 
for MED12-mutation-positive and –negative leiomyomas, respectively. To adjust for multiple comparisons, 
P < 0.00147 indicated statistical significance (the Bonferroni correction). CI = confidence interval; IQR = inter 
quartile range; HT = hormone therapy; NB = negative binomial; PID = pelvic inflammatory disease. 1One value 
missing. 2Three values missing.
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because of missing information. In addition, this study pooled all the MED12-mutation-negative leiomyomas into 
one group, although these lesions are likely to be heterogeneous due to the variety of the underlying genetic driv-
ers38, 39. These include HMGA2 rearrangements and biallelic inactivation of fumarate hydratase (FH), sometimes 
related to a germline mutation30. These two driver events and MED12 mutations seem to be mutually exclusive 
and lead to unique gene expression patterns28. It is conceivable that all three leiomyoma subtypes may differ 
also in view of clinical characters, as it is already established that HLRCC-related FH-deficient tumours often 
show atypical histological features, develop at an earlier age, and are more numerous7, while HMGA2–aberrant 
tumours tend to be larger than other leiomyomas40. It remains to be elucidated, how the associations identified in 
this study relate to all three subgroups. Answering this question would require even larger sample sets due to the 
rarity of subtypes other than MED12, as well as much more extensive molecular workup to adequately identify 
the FH and HMGA2 subgroups.
Clinical and molecular classification of uterine leiomyomas is likely to be important for developing targeted 
management strategies such as more effective drugs. This study confirmed the association of MED12 mutations 
with smaller leiomyoma size, multiplicity and conventional histotype, and revealed novel associations between 
the MED12-mutation status and leiomyoma location, PID, and parity. These findings emphasise the relevance of 
specific driver mutations in genesis and presentation of uterine leiomyomas.
Methods
Subjects. This study was approved by the appropriate Ethics Review Board of the Helsinki University 
Hospital (HUH), Finland, and conducted in accordance with the Declaration of Helsinki. All patients gave signed 
informed consents before entering the study. We collected uterine leiomyoma (n = 763) and corresponding 
normal myometrial tissue samples from patients (n = 244) who had ultrasound-diagnosed uterine leiomyomas 
and underwent hysterectomy in HUH during October 2013 and November 2015 for any medical indication. 
Pathologists (A.P. and R.B.) dissected the hysterectomy specimens and recorded the location and size (the larg-
est diameter) of the tumours. All feasible distinct tumours ≥1 cm in diameter and a piece of the corresponding 
normal myometrial tissue were harvested and stored as fresh frozen. In addition, a formalin-fixed paraffin-em-
bedded (FFPE) block from each tumour was prepared. The dissected hysterectomy specimens underwent routine 
diagnostic pathological scrutiny, and the pathology reports provided the histopathological diagnosis for the study 
samples. A gynaecological pathologist (R.B.) reviewed haematoxylin-eosin-stained FFPE-tissue sections of all 
suspected (based on the pathology reports) leiomyoma variants and classified them according to the WHO 2014 
criteria4.
Clinical data came from a retrospective review of medical records of all study subjects, and for 70 patients, 
from an additional designed questionnaire. Data included demographic information and medical and gynaeco-
logical history (Table 3).
Mutation analysis. All tumour and normal tissue samples underwent genomic DNA extrac-
tion with FastDNA Kit (MP Biomedicals LLC, Solon, OH, USA) and screening for MED12 exon 1 and 
2 mutations by Sanger sequencing using 5′ to 3′ primers CCTCCGGAACGTTTCATAGAT (forward) 
and TTCGGGACTTTTGCTCTCAC (reverse), and GCCCTTTCACCTTGTTCCTT (forward) and 
TGTCCCTATAAGTCTTCCCAACC (reverse), respectively. PCR products were sequenced using Big Dye 
Terminator v.3.1 sequencing chemistry (Applied Biosystems, Foster City, CA, USA) on an ABI3730 Automatic 
DNA Sequencer. We analysed sequence graphs manually and with Mutation Surveyor software (Softgenetics, 
State College, PA, USA).
Statistical methods. We employed R version 3.2.3 to perform statistical analyses41. Continuous variables 
were summarised as medians and ranges or inter quartile ranges (IQRs) due to non-normal distribution, and 
categorical variables as counts and percentages (Tables 2 and 3). We applied GEE, as well as Poisson and negative 
binomial regression, to obtain multivariable-adjusted effect size estimates (regression coefficients) accompanied 
by 95% confidence intervals (see Supplementary Information online for detailed information on the statistical 
models). In tumour-level analysis, MED12-mutation status (a binary variable) was predicted by tumour charac-
teristics (size, location and histotype). Considering that multiple leiomyomas within a uterus may not be inde-
pendent, we applied the GEE method with exchangeable correlation structure (80 observations deleted due to 
missing information, n = 683). The model was fit assuming the binomial random component and logit link func-
tion (geeglm function in R package geepack)42–44. Inferences of the GEE parameters were based on the Wald sta-
tistic. To model MED12-mutation-negative-leiomyoma counts, we applied Poisson regression (glm function in R, 
three observations deleted due to missing information, n = 241). In the model for MED12-mutation-positive leio-
myoma counts, we assumed the negative binomial distribution with quadratic variance function (glm.nb function 
in R package MASS, three observations deleted due to missing information, n = 241) to account for overdis-
persion in the corresponding Poisson model (evaluated using dispersiontest function in R package AER)45, 46. 
To assess whether the negative binomial distribution provided a better fit to these data, we used the likelihood 
ratio test to compare negative binomial and Poisson regression models (odTest function in R package pscl)47. The 
generalised Pearson statistic and model deviance were used to assess Poisson and negative binomial goodness of 
fit. In both models for tumour counts, we considered explanatory variables previously associated with leiomy-
oma risk and putative confounding variables [African origin, age at hysterectomy, menarche, menopausal status 
(premenopausal/current use of HT/postmenopausal, no HT), parity, infertility, smoking status, alcohol use, BMI, 
family history of leiomyomas, oral contraceptive use, history of PID and chlamydia, hypertension, thyroid dis-
order, diabetes, and prior leiomyoma surgery]. Variables with >10 missing values (menarche and alcohol use) 
or <5 cases (African origin) were omitted. Spearman correlation matrix (R package PerformanceAnalytics) and 
variance inflation factors (vif function in R package car) were computed to evaluate possible collinearity among 
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explanatory variables48, 49. A total of 34 statistical tests were undertaken to investigate the relationships between 
patient- or tumour-level variables and MED12 mutations. To adjust for multiple comparisons, we applied the 
Bonferroni correction (α = 0.05/34); two-sided P < 0.00147 indicated statistical significance.
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